

**6<sup>th</sup> Early Detection Research Network (EDRN) Scientific  
Workshop  
19<sup>th</sup> EDRN Steering Committee Meeting  
August 31 – September 3, 2009  
Doubletree Hotel Bethesda  
Bethesda, Maryland**

**Alliance of Glycobiologists for Detection of  
Cancer and Cancer Risk**

**Wednesday, September 2, 2009  
2:00 – 6:00 p.m.**

**Thursday, September 3, 2009  
8:30 a.m. – 12:00 p.m.**

**Ballroom C&D**

**Chairs:**

- William Hancock, Ph.D., Barnett Institute, Northeastern University
- Michael Pierce, Ph.D., University of Georgia

**Agenda**

**Wednesday, September 2, 2009**

- |                         |   |
|-------------------------|---|
| 2:00 – 2:15 p.m.        | Call to Order   |
| 2:15 – 2:30 p.m.        | <u>NCI Expectations and Deliverables</u> <ul style="list-style-type: none"><li>○ Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute</li><li>○ Karl Krueger, Ph.D., National Cancer Institute</li></ul> |
| 2:30 – 4:00 p.m.        | <u>Alliance Accomplishments</u><br>Each Member to speak for up to 10 minutes to enumerate major accomplishments   |
| <b>4:00 – 4:15 p.m.</b> | <b>Break</b>  |
| 4:15 – 6:00 p.m.        | <u>Discussion: Setting Goals and Deliverables: How can we maximize our chances of success of renewal?</u>   |

*Topics of Discussion:*

1. Identify a common objective and goal
2. Identify short-term (low hanging fruit) and long-term goals
3. Prioritize three to four most important goals for coming years
4. Identify resources elsewhere complementary to Alliance's goal
5. Develop a unified vision for the Alliance
6. Develop metrics for evaluation for Alliance as a whole and the individual grantee

**6<sup>th</sup> Early Detection Research Network (EDRN) Scientific  
Workshop  
19<sup>th</sup> EDRN Steering Committee Meeting  
August 31 – September 3, 2009  
Doubletree Hotel Bethesda  
Bethesda, Maryland**

**Alliance of Glycobiologists for Detection of  
Cancer and Cancer Risk**

**Wednesday, September 2, 2009 Continued**

**Discussion: Setting Goals and Deliverables: How can we maximize our  
chances of success of renewal? Continued**

*Questions to Facilitate Discussion:*

1. What is our timeline to prepare for renewal?
2. What would NCI view as a success for our consortium?
3. Are there examples of successes from other NCI consortia?
4. What biomarker panels do we have that could be close to validation?
5. How many laboratories have biomarkers that could feasibly be tested in blinded studies by summer 2011? At what stages in the EDRN phases of validation do our projects currently stand?
6. Are there any potential collaborations within our group or some of our peers (Brian Haab, David Lubman, etc.) that would aid the Alliance to meet the validation milestones?

**6:00 p.m.                      Adjourn**

**Thursday, September 3, 2009**

**8:30 – 10:15 a.m.              Lessons Learned in Diagnostic Research**

8:30 – 9:05 a.m.              Pitfalls to Biomarker Discovery  
David Ransohoff, M.D., University of North Carolina  
at Chapel Hill

9:05 – 9:40 a.m.              Sample Collection, Storage, and Preparation  
William Grizzle, M.D., Ph.D., University of Alabama  
at Birmingham

9:40 – 10:15 a.m.              Study Design  
Mark Thornquist, Ph.D., Fred Hutchinson Cancer  
Research Center

**10:15 – 10:30 a.m.              Break**

**6<sup>th</sup> Early Detection Research Network (EDRN) Scientific  
Workshop  
19<sup>th</sup> EDRN Steering Committee Meeting  
August 31 – September 3, 2009  
Doubletree Hotel Bethesda  
Bethesda, Maryland**

**Alliance of Glycobiologists for Detection of  
Cancer and Cancer Risk**

**Thursday, September 3, 2009 Continued**

10:30 – 12:00 p.m.      Discussion: Lessons learned in diagnostic research –  
How well prepared are we to start a validation study?

*Questions to Facilitate Discussion:*

1. What exactly is a validation study?
2. When are my biomarkers ready for a validation study?
3. What specimens will be needed to accomplish these validation studies? Are they available through EDRN clinical centers or as reference sets?
4. What does it mean if my biomarkers fail in a validation study?

**12:00 p.m.                      Adjourn**